NSE ALKEM · BSE 539523 · Biotechnology & Drugs · NIFTY 500
Alkem Laboratories Share Price
Alkem Laboratories Overview
Where the price stands, how it has moved and how it sits against its averages.
Alkem Laboratories shares last traded at ₹5,299.00 on the NSE, down 2.51% on the day. That is 10.7% below the 52-week high of ₹5,933.00 and 4.9% above the 52-week low of ₹5,052.05. Its market value is ₹63,106 Cr.
Price returns
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.
Moving averages — price is above 2 of 6
- 300-day average₹5,502.08 ▼ price 3.7% below
- 50-day average₹5,448.61 ▼ price 2.7% below
- 100-day average₹5,447.10 ▼ price 2.7% below
- 5-day average₹5,337.10 ▼ price 0.7% below
- Today's price₹5,299.00
- 20-day average₹5,260.18 ▲ price 0.7% above
- 10-day average₹5,239.20 ▲ price 1.1% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Alkem Laboratories Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹14,712 Cr | ▲ +13.5% | ₹2,302 Cr | 15.6% | ₹192.51 | ₹53.00 |
| FY 2025 | ₹12,965 Cr | ▲ +2.3% | ₹2,165 Cr | 16.7% | ₹181.11 | ₹45.00 |
| FY 2024 | ₹12,668 Cr | ▲ +9.2% | ₹1,796 Cr | 14.2% | ₹150.19 | ₹40.00 |
| FY 2023 | ₹11,599 Cr | ▲ +9.1% | ₹984 Cr | 8.5% | ₹82.31 | ₹25.00 |
| FY 2022 | ₹10,634 Cr | ▲ +20.0% | ₹1,646 Cr | 15.5% | ₹137.63 | ₹34.00 |
| FY 2021 | ₹8,865 Cr | ▲ +6.2% | ₹1,585 Cr | 17.9% | ₹132.57 | ₹30.00 |
| FY 2020 | ₹8,344 Cr | — | ₹1,127 Cr | 13.5% | ₹94.26 | ₹25.00 |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹3,740 Cr | ▲ +3.8% | ₹520 Cr | 13.9% | ₹43.49 |
| Q4 FY26 | ₹3,603 Cr | ▼ −3.6% | ₹236 Cr | 6.6% | ₹19.78 |
| Q3 FY26 | ₹3,737 Cr | ▼ −6.6% | ₹636 Cr | 17.0% | ₹53.19 |
| Q2 FY26 | ₹4,001 Cr | ▲ +18.7% | ₹765 Cr | 19.1% | ₹63.99 |
| Q1 FY26 | ₹3,371 Cr | ▲ +7.2% | ₹664 Cr | 19.7% | ₹55.56 |
| Q4 FY25 | ₹3,144 Cr | ▼ −6.8% | ₹306 Cr | 9.7% | ₹25.58 |
| Q3 FY25 | ₹3,374 Cr | ▼ −1.2% | ₹626 Cr | 18.5% | ₹52.34 |
| Q2 FY25 | ₹3,415 Cr | — | ₹689 Cr | 20.2% | ₹57.60 |
Balance sheet — FY26
- Total assets₹20,873 Cr
- Total liabilities₹7,053 Cr
- Shareholders' equity₹13,820 Cr
- Total debt₹2,047 Cr
- Cash & investments₹4,061 Cr
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 8,344.36 | 8,865.01 | 10,634.19 | 11,599.26 | 12,667.58 | 12,964.52 | 14,712.27 |
| Cost of revenue | 3,419.54 | 3,719.06 | 4,426.78 | 5,094.38 | 5,190.71 | 5,013.72 | 5,297.24 |
| Gross profit | 4,924.82 | 5,145.95 | 6,207.41 | 6,504.88 | 7,476.87 | 7,950.80 | 9,415.03 |
| Operating expenses | 7,057.36 | 7,195.53 | 8,862.68 | 10,320.11 | 10,681.06 | 10,796.71 | 12,189.32 |
| Operating income | 1,287.00 | 1,669.48 | 1,771.51 | 1,279.15 | 1,986.52 | 2,167.81 | 2,522.95 |
| Depreciation | 252.76 | 274.58 | 303.96 | 310.42 | 299.30 | 357.16 | 382.06 |
| Profit before tax | 1,259.79 | 1,842.10 | 1,844.28 | 1,304.77 | 2,023.13 | 2,526.41 | 2,868.92 |
| Tax | 110.48 | 224.33 | 163.96 | 297.96 | 211.67 | 311.03 | 517.76 |
| Net profit | 1,127.07 | 1,585.02 | 1,645.62 | 984.17 | 1,795.77 | 2,165.48 | 2,301.80 |
| EPS (₹) | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 |
| Dividend per share (₹) | 25.00 | 30.00 | 34.00 | 25.00 | 40.00 | 45.00 | 53.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 9,945.54 | 11,519.26 | 14,069.19 | 13,756.63 | 15,574.90 | 17,691.10 | 20,872.97 |
| Current assets | 5,505.65 | 6,928.82 | 8,435.43 | 8,729.68 | 10,411.58 | 10,945.82 | 12,210.52 |
| Cash & short-term investments | 460.29 | 1,753.70 | 1,313.03 | 1,143.16 | 3,802.32 | 3,777.92 | 4,061.45 |
| Inventory | 1,883.89 | 2,331.73 | 3,063.01 | 2,728.93 | 2,783.39 | 3,053.07 | 3,448.99 |
| Property, plant & equipment | 2,774.14 | 2,706.43 | 2,765.93 | 2,513.52 | 2,557.03 | 2,862.70 | 3,228.54 |
| Total liabilities | 3,784.87 | 4,142.53 | 5,431.29 | 4,711.34 | 5,262.84 | 5,706.23 | 7,052.87 |
| Current liabilities | 3,244.58 | 3,604.05 | 4,805.34 | 3,707.15 | 3,994.55 | 3,966.96 | 4,782.70 |
| Total debt | 1,722.67 | 1,791.98 | 2,668.19 | 1,396.68 | 1,418.41 | 1,380.90 | 2,047.16 |
| Total equity | 6,160.67 | 7,376.73 | 8,637.90 | 9,045.29 | 10,312.06 | 11,984.87 | 13,820.10 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 585.08 | 1,264.90 | 1,111.02 | 1,682.50 | 1,948.07 | 1,912.84 | 1,963.03 |
| From investing | −741.35 | −998.54 | −1,435.13 | 112.84 | −1,008.50 | −1,298.76 | −1,667.21 |
| From financing | 79.15 | −271.75 | 379.57 | −1,760.82 | −1,145.01 | −810.99 | −503.40 |
| Capital expenditure | −363.09 | −194.91 | −338.88 | −232.91 | −259.29 | −675.62 | −617.26 |
| Dividends paid | −439.56 | −334.78 | −421.91 | −529.52 | −540.49 | −504.62 | −613.70 |
| Net change in cash | −73.11 | −1.72 | 57.96 | 41.62 | −207.49 | −186.40 | −222.04 |
What Analysts Say
Recommendations from 20 analysts who cover Alkem Laboratories.
▲ 11 bullish (55.0%) · 6 hold (30.0%) · ▼ 3 bearish (15.0%)
Votes
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | ▲ +2 |
| Buy | 5 | 5 | 5 | 5 | 5 | — |
| Hold | 6 | 6 | 6 | 6 | 6 | — |
| Sell | 2 | 2 | 2 | 2 | 2 | — |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | — |
Analyst ratings are opinions, not a guarantee of returns.
Alkem Laboratories vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories | ₹5,299.00 | ▼ −2.51% | ₹63,106 Cr | — | — | — | — | — | This stock |
| Sun Pharmaceutical Industries | ₹1,850.00 | ▼ −0.80% | ₹4,43,867 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,620.50 | ▲ +0.25% | ₹2,55,394 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,930.10 | ▼ −1.00% | ₹1,87,518 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,395.40 | ▲ +1.12% | ₹1,12,729 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,175.05 | ▲ +0.47% | ₹1,17,212 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Alkem Laboratories Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Per share What each share stands for
The share price is 4.59× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Latest dividend₹10.00 per share · 7 Aug 2026
Corporate calendar
- MeetingAnnual General Meeting
- MeetingCOM
- BoardQuarterly Results
- Dividend₹10.00 per share · 500% · Final dividend
- BoardAudited Results & Final Dividend
- Dividend₹43.00 per share · 2,150% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- BoardQuarterly Results
Show 14 older events
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹8.00 per share · 400% · Final dividend
- MeetingPostal Ballot
- MeetingPostal Ballot
- BoardAudited Results & Final Dividend
- Dividend₹37.00 per share · 1,850% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- BoardQuarterly Results
- MeetingPostal Ballot
- Dividend₹5.00 per share · 250% · Final dividend
- Dividend₹35.00 per share · 1,750% · Interim dividend
- Dividend₹10.00 per share · 500% · Final dividend
- Dividend₹15.00 per share · 750% · Interim dividend
About Alkem Laboratories
Biotechnology & Drugs
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Key people
- Basudeo Narain SinghExecutive Chairman of the Board
- Nitin AgrawalPresident - Finance, Chief Financial Officer
- Manish NarangPresident - Legal, Compliance Officer, Company Secretary
- Sandeep SinghManaging Director, Executive Director
- Madhurima SinghExecutive Director
- Mritunjay Kumar SinghExecutive Director
Company facts
- NSE symbolALKEM
- BSE code539523
- ISININE540L01014
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹63,106 Cr
- Revenue (FY26)₹14,712 Cr
- Net profit (FY26)₹2,302 Cr
In the News
Recent headlines about Alkem Laboratories — they open on Mint in a new tab.
- Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | Eight stocks to buy
The Indian stock market is set to open lower on September 10, as global cues remain mixed. The Sensex and Nifty 50 ended the previous session down, with market analysts predicting further weakness unless certain support levels are reclaimed.
10 Sep 2026 · 4 min read · Mint ↗ - Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 31 July 2026
The Indian stock market is expected to open flat-to-positive, reflecting global cues. Nifty 50, Sensex showed gains in the previous session, with significant support and resistance levels outlined by analysts. Stocks recommended for purchase are Sona BLW Precision, Alkem Laboratories, and RBL Bank.
31 Jul 2026 · 2 min read · Mint ↗ - Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
20 Jul 2026 · 2 min read · Mint ↗ - Nifty Pharma jumps 14% YTD, outshines Nifty 50; is there more upside ahead?
The Nifty Pharma index has surged 14.53% YTD, outperforming the Nifty 50's 7.87% decline. Key drivers include improving earnings visibility and stable demand in domestic formulations, while geopolitical tensions and inflation concerns weigh on broader market sentiment.
15 Jul 2026 · 4 min read · Mint ↗ - US FDA sends SOS to Indian drugmakers for critical cancer medicine amid US shortage
The US FDA is trying to secure supplies of ifosfamide, a cancer treatment in short supply due to manufacturing disruptions. IDMA is gathering information on potential Indian suppliers to address the ongoing drug shortage in the US.
23 Jun 2026 · 5 min read · Mint ↗ - Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row
The Nifty Pharma index rose 1.4% on 8 June, defying the broader market selloff, supported by heavyweight stocks like JB Chemicals and Alkem Laboratories. Despite some losses in others, analysts suggest pharma stocks are resilient during market instability due to consistent healthcare demand.
8 Jun 2026 · 3 min read · Mint ↗ - Stocks to watch: Vedanta, Canara Bank, Adani Ports among 10 shares in focus today; check list here
Stock market today: The market is likely to snap its gaining streak as trends in the Gift Nifty index signalled a negative opening on Wednesday. Amid this backdrop, these stocks will remain in focus on 3 June.
3 Jun 2026 · 3 min read · Mint ↗ - Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?
The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.
21 May 2026 · 3 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →